Reviews

There are no reviews yet.

Be the first to review “Retatrutide 10mg”

Use the peptide calculator to determine exact reconstitution volumes and dosing schedules for your research protocol.

Retatrutide (LY3437943), developed by Eli Lilly, is a next-generation triple receptor agonist simultaneously targeting GLP-1, GIP, and glucagon receptors. Unlike semaglutide (GLP-1 only) or tirzepatide (dual GLP-1/GIP), retatrutide's glucagon receptor activity significantly increases energy expenditure, making it one of the most potent metabolic research compounds available. Phase II clinical trials demonstrated average weight reduction of 17.5% at 24 weeks and 24.2% at 48 weeks in the 12mg cohort — results that significantly exceed previously available compounds. Retatrutide represents a major advancement in the pharmacology of metabolic disease.

Molecular Data

Molecular Formula: C187H291N45O57 | Molecular Weight: 4130.6 g/mol | CAS Number: 2381606-29-3

Triple Receptor Mechanism

Retatrutide acts on three receptor pathways simultaneously: GLP-1 receptors stimulate insulin secretion and suppress appetite; GIP receptors (at 8.9× the potency of endogenous GIP) enhance insulin response and energy storage regulation; and glucagon receptors increase hepatic glucose output and energy expenditure. This triple mechanism produces effects on appetite, insulin sensitivity, and metabolic rate that are synergistically greater than any single or dual pathway approach.

Clinical Trial Data

In the pivotal Phase II obesity trial, participants receiving 12mg weekly retatrutide achieved mean weight loss of 17.5% at 24 weeks and 24.2% at 48 weeks. Secondary outcomes included significant improvements in triglycerides, HDL cholesterol, blood pressure, and fasting glucose. The compound is currently in Phase III TRIUMPH trials evaluating long-term safety and efficacy. Improvements in liver steatosis (MASLD) have also been documented in a sub-study of the Phase II trial.

Comparison to Other GLP-1 Compounds

Retatrutide's triple agonism provides meaningfully superior weight reduction compared to semaglutide (GLP-1 mono-agonist, ~15% weight loss at 68 weeks) and tirzepatide (GLP-1/GIP dual agonist, ~21% at 72 weeks in SURMOUNT-1). The addition of glucagon receptor activity drives increased energy expenditure through thermogenesis — a mechanism absent in the other compounds — accounting for much of the additional efficacy observed.

Metabolic and Hepatic Effects

Beyond weight reduction, retatrutide demonstrates significant hepatic benefits. Research in patients with metabolic dysfunction-associated steatotic liver disease (MASLD) shows meaningful reductions in liver fat content, hepatic inflammation markers (ALT, AST), and fibrosis biomarkers. These effects are attributed to the combined action of GLP-1 mediated insulin sensitisation and glucagon receptor activation improving hepatic lipid metabolism.

Future Research

Retatrutide is currently progressing through Phase III TRIUMPH clinical trials. Research interest extends beyond obesity to type 2 diabetes, MASLD, cardiovascular risk reduction, and potentially kidney disease. The triple agonist approach has established a new paradigm in metabolic peptide pharmacology.

Retatrutide 10mg